This segment focuses on the research and development of innovative pharmaceutical products, including small molecule drugs, biologics, and diagnostic reagents. R&D activities encompass drug discovery, preclinical studies, clinical trials, and regulatory submissions. Livzon utilizes advanced technologies such as siRNA-based therapies and proton pump inhibitors. The therapeutic areas covered include gastroenterology, oncology, and infectious diseases. The company aims to improve patient outcomes by providing effective treatments for various diseases. Livzon's market positioning is strengthened by its significant investment in R&D and its focus on innovative therapies. Future opportunities lie in expanding the product pipeline and entering new therapeutic areas. Regulatory aspects include obtaining approvals from the National Medical Products Administration (NMPA) for clinical trials and product launches. Partnerships and collaborations are essential for accessing new technologies and expanding market reach.

This segment involves the manufacturing, marketing, and distribution of pharmaceutical products. It includes the production of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. Livzon employs advanced manufacturing processes to ensure product quality and efficiency. The company's product portfolio includes a wide range of drugs for various therapeutic areas, such as duodenal ulcers, reflux esophagitis, schizophrenia, and upper respiratory tract infections. The patient impact is significant, as Livzon's products provide essential treatments for a broad patient population. The company's market positioning is enhanced by its comprehensive product portfolio and strong distribution network. Future opportunities include expanding into overseas markets and increasing market share in China. Regulatory compliance is crucial, and the company adheres to strict manufacturing standards. Partnerships with distributors and retailers are essential for effective commercialization.

This segment focuses on the development, manufacturing, and commercialization of diagnostic reagents and kits. Livzon offers a range of diagnostic products, including kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for HIV-1, antinuclear antibody test kits, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibody. The company utilizes advanced technologies such as immunoassay and molecular diagnostics. The therapeutic areas covered include infectious diseases and immunology. The patient impact is significant, as these diagnostics aid in the early detection and diagnosis of various diseases. Livzon's market positioning is strengthened by its focus on high-quality diagnostic products and its ability to respond to emerging health threats. Future opportunities include expanding the product portfolio and entering new diagnostic areas. Regulatory compliance is essential, and the company must obtain necessary approvals for its diagnostic products. Partnerships with healthcare providers and laboratories are crucial for market access and distribution.